EGR1 Regulates Cellular Metabolism and Survival in Endocrine Resistant Breast Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Dec 13

PMID 29228577

Citations 23

Authors

Ayesha N Shajahan-Haq

Simina M Boca

Lu Jin

Krithika Bhuvaneshwar

Yuriy Gusev

Amrita K Cheema

Diane D Demas

Kristopher S Raghavan

Ryan Michalek

Subha Madhavan

Robert Clarke

Affiliations

Soon will be listed here.

Abstract

About 70% of all breast cancers are estrogen receptor alpha positive (ER+; ESR1). Many are treated with antiestrogens. Unfortunately, and acquired resistance to antiestrogens is common but the underlying mechanisms remain unclear. Since growth of cancer cells is dependent on adequate energy and metabolites, the metabolomic profile of endocrine resistant breast cancers likely contains features that are deterministic of cell fate. Thus, we integrated data from metabolomic and transcriptomic analyses of ER+ MCF7-derived breast cancer cells that are antiestrogen sensitive (LCC1) or resistant (LCC9) that resulted in a gene-metabolite network associated with EGR1 (early growth response 1). In human ER+ breast tumors treated with endocrine therapy, higher EGR1 expression was associated with a more favorable prognosis. Mechanistic studies showed that knockdown of EGR1 inhibited cell growth in both cells and EGR1 overexpression did not affect antiestrogen sensitivity. Comparing metabolite profiles in LCC9 cells following perturbation of EGR1 showed interruption of lipid metabolism. Tolfenamic acid, an anti-inflammatory drug, decreased EGR1 protein levels and synergized with antiestrogens in inhibiting cell proliferation in LCC9 cells. Collectively, these findings indicate that EGR1 is an important regulator of breast cancer cell metabolism and is a promising target to prevent or reverse endocrine resistance.

Citing Articles

Metabolic Switch in Endocrine Resistant Estrogen Receptor Positive Breast Cancer.

Brechbuhl H, Han A, Paul K, Nemkov T, Ramachandran S, Ward A bioRxiv. 2025; .

PMID: 39763830 PMC: 11703175. DOI: 10.1101/2024.12.28.630631.

Photolysis of tolfenamic acid in aqueous and organic solvents: a kinetic study.

Kazi S, Sheraz M, Anwar Z, Musharraf S, Ahmed S, Bano R RSC Adv. 2024; 14(30):21383-21397.

PMID: 38979457 PMC: 11228578. DOI: 10.1039/d4ra01369g.

The Human Intermediate Prolactin Receptor I-tail Contributes Breast Oncogenesis by Targeting Ras/MAPK Pathway.

Shen S, Radhakrishnan S, Harrell J, Puchalapalli M, Koblinski J, Clevenger C Endocrinology. 2024; 165(6).

PMID: 38713636 PMC: 11492283. DOI: 10.1210/endocr/bqae039.

Comparative Analysis of Transcriptomic Changes including mRNA and microRNA Expression Induced by the Xenoestrogens Zearalenone and Bisphenol A in Human Ovarian Cells.

Marton E, Varga A, Penyige A, Birko Z, Balogh I, Nagy B Toxins (Basel). 2023; 15(2).

PMID: 36828454 PMC: 9967916. DOI: 10.3390/toxins15020140.

GDNF-RET signaling and EGR1 form a positive feedback loop that promotes tamoxifen resistance via cyclin D1.

Marks B, Pipia I, Mukai C, Horibata S, Rice E, Danko C BMC Cancer. 2023; 23(1):138.

PMID: 36765275 PMC: 9912664. DOI: 10.1186/s12885-023-10559-1.

References

Xia J, Sinelnikov I, Han B, Wishart D . MetaboAnalyst 3.0--making metabolomics more meaningful. Nucleic Acids Res. 2015; 43(W1):W251-7. PMC: 4489235. DOI: 10.1093/nar/gkv380. View

Clarke R, Skaar T, Bouker K, Davis N, Lee Y, Welch J . Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol. 2001; 76(1-5):71-84. DOI: 10.1016/s0960-0760(00)00193-x. View

Kim H, Cho S, Kim J, Kim S, Choi C, Kim J . Apoptotic effect of tolfenamic acid on MDA-MB-231 breast cancer cells and xenograft tumors. J Clin Biochem Nutr. 2013; 53(1):21-6. PMC: 3705153. DOI: 10.3164/jcbn.12-78. View

Tao W, Shi J, Zhang Q, Xue B, Sun Y, Li C . Egr-1 enhances drug resistance of breast cancer by modulating MDR1 expression in a GGPPS-independent manner. Biomed Pharmacother. 2013; 67(3):197-202. DOI: 10.1016/j.biopha.2013.01.001. View

Cline M, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C . Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007; 2(10):2366-82. PMC: 3685583. DOI: 10.1038/nprot.2007.324. View

Gaggioli C, Robert G, Bertolotto C, Bailet O, Abbe P, Spadafora A . Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. J Invest Dermatol. 2006; 127(2):400-10. DOI: 10.1038/sj.jid.5700524. View

Kamburov A, Cavill R, Ebbels T, Herwig R, Keun H . Integrated pathway-level analysis of transcriptomics and metabolomics data with IMPaLA. Bioinformatics. 2011; 27(20):2917-8. DOI: 10.1093/bioinformatics/btr499. View

Dabydeen S, Kang K, Diaz-Cruz E, Alamri A, Axelrod M, Bouker K . Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance. Carcinogenesis. 2014; 36(1):122-32. PMC: 4291054. DOI: 10.1093/carcin/bgu237. View

Schwartz-Roberts J, Shajahan A, Cook K, Warri A, Abu-Asab M, Clarke R . GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther. 2013; 12(4):448-59. PMC: 3624027. DOI: 10.1158/1535-7163.MCT-12-0617. View

10.

PRATT M, Satkunaratnam A, Novosad D . Estrogen activates raf-1 kinase and induces expression of Egr-1 in MCF-7 breast cancer cells. Mol Cell Biochem. 1999; 189(1-2):119-25. DOI: 10.1023/a:1006827015320. View

11.

Hilakivi-Clarke L, Warri A, Bouker K, Zhang X, Cook K, Jin L . Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model. J Natl Cancer Inst. 2016; 109(1). PMC: 6255695. DOI: 10.1093/jnci/djw188. View

12.

Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S . The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. Mol Cancer Ther. 2009; 8(5):1207-17. PMC: 2939312. DOI: 10.1158/1535-7163.MCT-08-1097. View

13.

Thigpen A, Cala K, Guileyardo J, Molberg K, McConnell J, Russell D . Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma. J Urol. 1996; 155(3):975-81. View

14.

Clarke R, Liu M, Bouker K, Gu Z, Lee R, Zhu Y . Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003; 22(47):7316-39. DOI: 10.1038/sj.onc.1206937. View

15.

Josefsen K, Sorensen L, Buschard K, Birkenbach M . Glucose induces early growth response gene (Egr-1) expression in pancreatic beta cells. Diabetologia. 1999; 42(2):195-203. DOI: 10.1007/s001250051139. View

16.

Brunner N, Boysen B, Jirus S, Skaar T, Holst-Hansen C, Lippman J . MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 1997; 57(16):3486-93. View

17.

Hansen P . Tolfenamic acid in acute and prophylactic treatment of migraine: a review. Pharmacol Toxicol. 1994; 75 Suppl 2:81-2. DOI: 10.1111/j.1600-0773.1994.tb02005.x. View

18.

Shajahan A, Riggins R, Clarke R . The role of X-box binding protein-1 in tumorigenicity. Drug News Perspect. 2009; 22(5):241-6. PMC: 3510657. DOI: 10.1358/dnp.2009.22.5.1378631. View

19.

Bae S, Bae M, Ahn M, Son M, Lee Y, Bae M . Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Cancer Res. 1999; 59(23):5989-94. View

20.

Liu C, Chen S, Wang X, Chen Y, Tang N . 15d-PGJ₂ decreases PGE₂ synthesis in HBx-positive liver cells by interfering EGR1 binding to mPGES-1 promoter. Biochem Pharmacol. 2014; 91(3):337-47. DOI: 10.1016/j.bcp.2014.07.032. View